Dragonfly Therapeutics, Inc. has entered into a new agreement with Celgene Corp. to discover, develop and commercialize immunotherapies for solid and hematological cancers. The agreement expands Celgene’s existing four-target collaboration with Dragonfly from 2017, and increases the number of TriNKET immunotherapy drug candidates available for in licensing by Celgene to a total of eight.   The new deal gives Celgene the option to license exclusive worldwide rights to products developed u...